Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

PemvidutidevsTirzepatide

Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

Weight ManagementWeight Management

At a Glance

Quick
comparison

Dose Range

Pemvidutide

1.2 mg–2.4 mg mg

Tirzepatide

2.5–15 mg

Frequency

Pemvidutide

Once daily

Tirzepatide

Once weekly

Administration

Pemvidutide

Subcutaneous injection

Tirzepatide

Subcutaneous injection

Cycle Length

Pemvidutide

Ongoing/indefinite

Tirzepatide

Ongoing/indefinite

Onset Speed

Pemvidutide

Moderate (1-2 weeks)

Tirzepatide

Moderate (1-2 weeks)

Evidence Level

Pemvidutide

Moderate human trials (Phase 1-2)

Tirzepatide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

Pemvidutide
Tirzepatide

Weight Loss

Pemvidutide92%
Tirzepatide99%

Liver Health

Pemvidutide95%
Tirzepatide0%

Metabolic Health

Pemvidutide88%
Tirzepatide0%

Appetite Control

Pemvidutide0%
Tirzepatide97%

Blood Sugar Control

Pemvidutide0%
Tirzepatide96%

Technical Data

Compound
specifications

Pemvidutide

Molecular Formula

C182H275N39O54

Molecular Weight

3873.35 Da

Half-Life

Approximately 110 hours (4.6 days)

Bioavailability

Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics

CAS Number

2538014-94-5

Tirzepatide

Molecular Formula

C225H348N48O68

Molecular Weight

4813.45 g/mol

Half-Life

Approximately 5 days (120 hours)

Bioavailability

~80% (subcutaneous)

CAS Number

2023788-19-2

Protocols

Dosing
tiers

Pemvidutide

Tirzepatide

starting

2.5 mg

Once weekly

4 weeks

This introductory dose helps your body adjust to the medication and minimizes GI side effects. Don't expect much weight loss yet—this phase is all about building tolerance. Think of it as your body's training wheels period.

standard

5-10 mg

Once weekly

4+ weeks at each dose

After 4 weeks at 2.5mg, increase to 5mg. Stay here for at least 4 weeks, then move to 7.5mg, then 10mg. This gradual climb reduces side effects while ramping up the weight loss. Most people start seeing serious results at 5-10mg doses.

advanced

12.5-15 mg

Once weekly

Ongoing/maintenance

The 15mg dose delivers maximum weight loss—averaging over 20% of body weight in trials. Continue increasing by 2.5mg every 4 weeks until reaching 15mg or your optimal maintenance dose. This is where the jaw-dropping results happen.

Applications

Best
suited for

Pemvidutide

Adults seeking substantial weight loss without complex dose titration

Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy

Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients with metabolic syndrome who need comprehensive risk factor improvement

Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Those interested in investigational dual agonist therapies with strong early data

Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Tirzepatide

People Who Want Maximum Weight Loss Results

If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close.

Those Who Haven't Succeeded with Semaglutide

Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss.

People with Type 2 Diabetes Needing Aggressive Control

Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health.

Individuals Looking to Transform Their Relationship with Food

Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you.

Safety Profile

Side
effects

Pemvidutide

Common

  • Nausea
  • Diarrhea
  • Headache

Uncommon

  • Vomiting
  • Decreased Appetite

Serious

  • Acute Pancreatitis
  • Severe Gastrointestinal Disturbance

Tirzepatide

Common

  • Nausea
  • Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Thinning (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research Status

Safety
& evidence

Pemvidutide

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Pemvidutide (rzenx, Eli Lilly GLP-1/GCG dual agonist) completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.

Contraindications

  • xPersonal or family history of medullary thyroid carcinoma or MEN2 syndrome
  • xKnown hypersensitivity to pemvidutide or formulation components
  • xHistory of acute pancreatitis
  • xSevere hepatic decompensation (Child-Pugh C cirrhosis)

Tirzepatide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.

Contraindications

  • xPersonal or family history of medullary thyroid carcinoma (MTC)
  • xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
  • xCurrent or recent pancreatitis
  • xPregnancy or planning to become pregnant

Decision Guide

Which is
right for you?

Choose Pemvidutide if...

  • Adults seeking substantial weight loss without complex dose titration
  • Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
  • Patients with metabolic syndrome who need comprehensive risk factor improvement
  • Those interested in investigational dual agonist therapies with strong early data

Choose Tirzepatide if...

  • Maximum weight loss results
  • Long-term obesity management
  • Type 2 diabetes control
  • Metabolic health improvement